Category Archives: Mesenchymal Stem Cells

Stem cells broke into the public consciousness in the early 1990s, but progress has been slow. Photo: Bloomberg Edgar Irastorza was just 31 when his heart stopped beating in October 2008. A Miami property manager, break-dancer and former high school wrestler, Irastorza had recently gained weight as his wife's third pregnancy progressed. "I kind of got pregnant, too," he said. During a workout one day, he felt short of breath and insisted that friends rush him to the hospital. Minutes later, his pulse flatlined. He survived the heart attack, but the scar tissue that resulted cut his heart's pumping ability by a third. He couldn't pick up his children. He couldn't dance. He fell asleep every night wondering if he would wake up in the morning. Desperation motivated Irastorza to volunteer for a highly unusual medical research trial: getting stem cells injected directly into his heart. "I just trusted my doctors and the science behind it, and said, 'This is my only chance,'" he said recently. Over the past five years, by studying stem cells in lab dishes, test animals and intrepid patients like Irastorza, researchers have brought the vague, grandiose promises of stem cell therapies closer to reality. Stem … Continue reading →

Dallas, TX (PRWEB) September 15, 2014 Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc. Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients. Order a copy of this report at http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114908 . The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in … Continue reading →

GIOSTAR- STEM CELL THERAPY DR ANAND SHRIVASTAVA Global Institute of Stem cell Therapy and Research - GIOSTAR Introduction to Stem Cell Therapy, and Dr.Anand Shrivastava - Chairman Co-founder of GIOSTAR. By: Devang Parmar … Continue reading →

Prof. Alexander Smikodub MD Ph.D Alexander Smikodub jr. MD Ph.D Our clinic offers the advanced and patented methods of fetal stem cell treatment for various conditions and diseases. This method of treatment can be found in wikipedia: Stem cell therapy. Fetal stem cells are non-specialized cells that differentiate (turn) into any other cell type of the body that form organs and tissues. Fetal stem cells that we use for treatment have huge potential for growth, differentiation and are not rejected by the patients body, which allows to achieve unique long-term clinical effects. We have more than 15 years of experience in stem cell therapy and are the leaders of the industry. Most of the methodic used in the clinic are unique and patent protected in many countries including USA. Since 1994 prof. Alexander Smikodub Sr. was the main researcher, doctor and administrator of the clinic. Now his son, Alexander Smikodub Jr. M.D. continues his fathers venture. During these years more than 6500 patients from all over the world received fetal stem cell treatment, resulting in significant improvement of their conditions, and in case of timely contact with us in complete cure of the diseases still considered lethal by most medical … Continue reading →

(PRWEB UK) 11 September 2014 Without doubt the best stem cells are those found in the baby teeth of young children. Why? Apart from their unique ability to morph and change into other stem cells, thus treating a far wider range of illnesses and conditions, mesenchymal stem cells can proliferate outside the body, and where children are concerned no tooth extraction is needed as they fall out naturally. Above all it is important to remember that the best type of cells are those which are young, and therefore have not been contaminated by a lifetime of use and exposure. So does that mean for adults there is no hope for stem cell retrieval from their adult teeth and little chance of success if they are needed in stem cell therapy? Not necessarily, says Mike Byrom, Chief Scientific Officer at specialist tooth stem cell bank, BioEden. Stem cell therapy is not a black and white type of event. There are varying degrees of success based on many factors of which the capacity of the cells is one. The functional capacity of a 44 year old cell is not as good as that of a 6 year old but that does not … Continue reading →

'So far appears safe, without side effects' (ANSA) - Boston, September 9 - Mesenchymal stem cell therapy to treat multiple sclerosis so far appears safe and without side effects, according to data released Tuesday and obtained through clinical trials on patients as part of the international Mesems project coordinated by University of Genoa neurologist Antonio Uccelli. The results were announced ahead of the World Congress on Treatment and Research in Multiple Sclerosis opening in Boston Wednesday through Saturday. The Mesems project involves researchers from nine countries - Italy, Spain, France, Britain, Sweden, Denmark, Switzerland, Canada and Australia. It is the first large phase II international multicentre clinical trial to determine the safety of a consensus treatment protocol established by the International Mesenchymal Stem Cells Transplantation Study Group to obtain information on its effectiveness on multiple sclerosis patients. So far, 81 patients have been involved in the project - half of the 160 needed for the whole clinical trial. About 73 - or 90% of those involved in blind testing - were given at least one injection with mesenchymal therapy or got a placebo while 51 - or 63% - were given both injections and 27 - 33% - completed the … Continue reading →

Freeport, Grand Bahama (PRWEB) September 08, 2014 Adult stem cell therapy for heart disease has emerged as a new treatment alternative for those living with a poor quality of life as a result of severe coronary artery disease. Okyanos is slated to begin delivering this innovative new treatment in the next several weeks, and is now screening qualified heart disease candidates. The procedure will be performed in their newly constructed state-of-the-art Phillips catheterization lab, as announced last month. Just 50 miles from US shore, Okyanos cardiac cell therapy is available to qualified patients with advanced stages of coronary artery disease (CAD) and congestive heart failure (CHF). The screening process consists of a thorough review of your medical history by the Okyanos Chief Medical Officer and Cardiologist, Dr. Howard Walpole, as well as consultation done in conjunction with your cardiologist. You must be able to travel as the protocol is delivered in Freeport on Grand Bahama Island. "As a leader in cardiac cell therapy, Okyanos is very excited to bring this innovative treatment and new standard of care to patients in a near-shore, regulated jurisdiction, said Matt Feshbach, CEO and co-founder of Okyanos. Our innovative treatment will restore blood flow to … Continue reading →

Tampa, FL (PRWEB) September 04, 2014 On Tuesday, September 9, the Lung Institute will hold an inaugural Stem Cell Social at its Tampa location. The Lung Institute created this event to address how stem cell treatment can help lung disease sufferers. Attendees will have the opportunity to learn how stem cell therapy can help, as well as set up a free consultation. In addition, a number of recent patients will be present to share how stem cell therapy has personally impacted their lives by repairing damaged lung tissue and improving function. As a leader in regenerative medicine, the Lung Institute has provided almost 300 stem cell treatments to lung disease patients who previously had no hope for better breathing and regaining quality of life. The Lung Institute treats lung diseases including pulmonary fibrosis and chronic obstructive pulmonary disease (COPD), a progressive disease that causes difficulty breathing, and is the third leading cause of death in the United States. Led by Dr. Burton Feinerman, a world-renowned physician in the field of regenerative medicine, the Lung Institute offers minimally invasive, and outpatient stem cell treatments for patients with a variety of debilitating lung diseases. Stem cells are taken from the patients own … Continue reading →

PUBLIC RELEASE DATE: 4-Sep-2014 Contact: Laia Cendrs laia.cendros@crg.eu 34-933-160-237 Center for Genomic Regulation This news release is available in Spanish. The protein Nanog, a transcription factor, is key to maintaining stem cells in a pluripotent state. Researchers from the Centre for Genomic Regulation have been investigating the role of this protein, and have just published an article in the prestigious journal Cell Reports where they reveal the mechanism whereby Nanog acts. The scientists have discovered that Nanog involves other agents and they have been able to detail their dynamics. In particular, by studying another protein that is also involved in cell reprogramming (beta-catenin) they have been able to improve the knowledge of Nanog's functioning. Cell renewal is a natural process that takes place constantly in our body. For this to happen, we have stem cells that are responsible for generating new cells to replenish and renew those that die. Stem cells give rise to undifferentiated pluripotent cells which have the ability to become any cell type. These pluripotent cells follow a differentiation path towards specialisation, which can produce any cell type from neurones to skin. The scientists want to understand the mechanisms that allow stem cells to either differentiate or … Continue reading →

Friday, September 05 11:49:24 New research from NUI Galway is using adult stem cells in the fight against cornea transplant rejection. The research has been published in the American Journal of Transplantation, and underpins a pan-European project which hopes to help the 100,000 people worldwide who undergo cornea transplant procedures each year. Corneal eye disease is the fourth most common cause of blindness in the world and it affects more than 10 million people worldwide. An unhealthy cornea affects vision by scattering or distorting light and causing glare and blurred vision. The most widely used treatment for this condition is cornea transplantation (or keratoplasty) where the diseased or scarred corneal tissue is replaced with healthy tissue from an organ donor. Although these procedures have been performed for over 100 years, unfortunately about 30pc of transplants are unsuccessful due to rejection by the patient's own immune system. Researchers, led by Dr Thomas Ritter from NUI Galway's Regenerative Medicine Institute (REMEDI), showed in a model system that transplant rejection rates could be reduced to as low as 10pc by administering a certain type of stem cell called a mesenchymal stem cell (MSC). MSCs can be readily obtained and grown from the bone … Continue reading →